Group 1 - The company expects a net profit attributable to the parent company for the first half of 2025 to be between -55 million yuan and -46 million yuan, indicating a significant loss compared to a profit of 25.45 million yuan in the same period last year [2][3] - The expected net profit excluding non-recurring gains and losses for the first half of 2025 is also projected to be between -55 million yuan and -46 million yuan [2][3] - The decline in performance is primarily attributed to a decrease in sales revenue of safety syringes and pre-filled catheter flushing devices due to the impact of the "He Qinghong seal engraving incident" and U.S. tariff policies, leading to a 40% drop in export revenue and an 82% decline in gross profit for safety syringes [2][3] Group 2 - The company has further made a provision for inventory impairment of approximately 20 million yuan for pre-filled catheter flushing devices and safety syringes based on cautious principles and current market sales conditions [3] - The sales revenue of pre-filled catheter flushing devices and safety syringes (domestic sales) has decreased by approximately 92% compared to the same period last year, significantly reducing the profits from these products [2][3] - The performance forecast is based on preliminary estimates and has not been audited by an accounting firm, with no significant uncertainties expected to affect the accuracy of the forecast [3]

[Current Period Performance Forecast](index=1&type=section&id=Item%20I.%20Current%20Period%20Performance%20Forecast) The company forecasts a net loss for H1 2025, with attributable net profit expected between -55 million and -46 million yuan, a stark reversal from the prior year's profit H1 2025 Performance Forecast vs. Prior Year | Indicator | H1 2025 (Forecast) | H1 2024 (Prior Year) | | :--- | :--- | :--- | | Net Profit Attributable to Parent Company (Million Yuan) | -55 to -46 | 25.4450 | | Net Profit Attributable to Parent Company (Excluding Non-Recurring Items) (Million Yuan) | -55 to -46 | 24.4007 | - This performance forecast is a preliminary estimate based on the company's operating conditions and has not been audited by a certified public accounting firm[4](index=4&type=chunk) [Prior Period Operating Performance](index=1&type=section&id=Item%20II.%20Prior%20Period%20Operating%20Performance) In H1 2024, the company reported a net profit of **25.4450 million yuan** attributable to the parent company, with earnings per share of **0.05 yuan** H1 2024 Performance Review | Indicator | Amount | | :--- | :--- | | Net Profit Attributable to Parent Company (Million Yuan) | 25.4450 | | Net Profit Attributable to Parent Company (Excluding Non-Recurring Items) (Million Yuan) | 24.4007 | | Earnings Per Share (Yuan) | 0.05 | [Main Reasons for Current Period Loss Forecast](index=2&type=section&id=Item%20III.%20Main%20Reasons%20for%20Current%20Period%20Loss%20Forecast) The H1 2025 loss is primarily due to declining export sales from US tariffs, a severe impact on domestic sales from the "He Qinghong Private Seal Incident," and significant inventory impairment provisions [Impact of US Tariffs: Decline in Export Business](index=2&type=section&id=3.1%20Impact%20of%20US%20Tariffs) US tariff policies severely impacted the export business of safety syringes, resulting in significant declines in both revenue and gross profit - Export revenue for safety syringes declined by approximately **40%**[7](index=7&type=chunk) - Export gross profit for safety syringes declined by approximately **82%**[7](index=7&type=chunk) [Impact of “He Qinghong Private Seal Incident”: Decline in Domestic Business](index=2&type=section&id=3.2%20Impact%20of%20%E2%80%9CHe%20Qinghong%20Private%20Seal%20Incident%E2%80%9D) The "He Qinghong Private Seal Incident" severely disrupted domestic sales channels, causing a sharp decline in revenue for pre-filled catheter flush syringes and safety syringes - Sales revenue for pre-filled catheter flush syringes and safety syringes (domestic sales) declined by approximately **92%** compared to the prior year due to this incident[8](index=8&type=chunk) [Provision for Inventory Impairment](index=2&type=section&id=3.3%20Provision%20for%20Inventory%20Impairment) Due to challenging market conditions and prudence, an additional **20 million yuan** inventory impairment provision was made for pre-filled catheter flush syringes and safety syringes, worsening the current loss - An additional inventory impairment provision of approximately **20 million yuan** was made for existing pre-filled catheter flush syringes and safety syringes[9](index=9&type=chunk) [Risk Warning and Other Notes](index=2&type=section&id=Item%20IV.%20Risk%20Warning%20and%20Other%20Notes) This performance forecast is preliminary and unaudited, with final financial data subject to the official H1 2025 report, urging investors to consider associated risks - This performance forecast is a preliminary estimate, unaudited by an accounting firm, and the company anticipates no significant uncertainties affecting its accuracy[10](index=10&type=chunk) - The specific and accurate financial data will be based on the company's officially disclosed H1 2025 report[11](index=11&type=chunk)

证券代码：603222 证券简称：济民健康 公告编号：2025-034 济民健康管理股份有限公司 关于回复《上海证券交易所关于公司 2024 年年 度报告的事后审核问询函》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 济民健康管理股份有限公司（以下简称："公司"）于近期收到上海证券交 易所下发的《关于济民健康管理股份有限公司 2024 年年度报告的事后审核问询 函》（上证公函【2025】0885 号）。公司收到年报问询函后高度重视，会同天 健会计师事务所（特殊普通合伙）就年报问询函提及的问题进行了逐项分析、核 实，现对相关问题回复如下： （一）涉案经销商名称、协议签订时间、涉及产品种类、金额/数量，截至 目前实际发生的退货比例及对应的资金补偿金额，相关《补充协议》法律效力及 与相关方沟通情况，并说明公安机关立案后的最新案件进展和公司已采取的应 对措施。 1、"何清红等人伪造公司印章"案涉案经销商情况 "何清红等人伪造公司印章"案涉及的产品主要为预充式导管冲洗器和安全 注射器，涉及的经销商分为两类，一级经销商和二级经销 ...

目 录 | 一、关于非标意见……………………………………………………第 | 1—9 | 页 | | --- | --- | --- | | 二、关于存货及销售情况 …………………………………………第 | 9—21 | 页 | | 三、关于商誉………………………………………………………第 | 21—32 | 页 | | 四、关于长期待摊费用……………………………………………第 | 32—37 | 页 | | 五、关于其他应收款………………………………………………第 | 37—43 | 页 | 问询函专项说明 天健函〔2025〕715 号 上海证券交易所： 由济民健康管理股份有限公司（以下简称济民健康或公司）转来的《关于济 民健康管理股份有限公司 2024 年年度报告的事后审核问询函》（上证公函【2025】 0885 号，以下简称问询函）奉悉。我们已对问询函中需要我们说明的财务事项 进行了审慎核查，现汇报说明如下。 本说明中除非另有说明，金额单位均为人民币万元；数值若出现合计数与各 分项加计之和尾数不符的情况，系由计算过程中四舍五入所致。 一、关于非标意见 年报及临时公告显示，公司原副总裁何清红及其团队涉嫌私刻公 ...

证券代码：603222 证券简称：济民健康 公告编号：2025-033 济民健康管理股份有限公司 2025 年 6 月，公司未实施回购。截止 2025 年 6 月 30 日，公司通过集中竞价 交易方式累计回购股份 2,005,500 股，占公司总股本的比例为 0.3819%，购买的最 高价为 6.13 元/股，最低价为 5.87 元/股，已支付的总金额为 12,088,967.50 元 （不含交易费用）。上述回购符合相关法律法规的规定及公司既定的回购股份方 案。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 | 回购方案首次披露日 | 2025/3/29 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 个月 12 | | 预计回购金额 | 10,000万元~20,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司 ...

Group 1 - The company held its 19th meeting of the 5th Board of Directors on June 15, 2025, via telecommunication, with all 7 directors present, confirming the meeting's legality [2][10] - The board approved two resolutions: the termination of the investment in an industrial fund and the participation in an entrepreneurial development fund, both with unanimous votes [3][10] Group 2 - The company initially planned to establish an industrial investment fund with a total subscription amount of 50 million RMB, with the company contributing 49.95 million RMB [7] - The decision to terminate the investment in the industrial fund was made after careful consideration and discussions with partners, with no actual capital contribution made by the company [9][10] - The termination of the investment will not affect the company's daily operations or harm the interests of shareholders [9] Group 3 - The company plans to invest 15 million RMB in the Hubei Changhe Intelligent Technology Entrepreneurial Development Partnership, which is part of a larger investment of 31 million RMB involving other partners [13][14] - This investment is aimed at leveraging external professional investment resources to support the company's industrial transformation and development [23][24] - The investment does not constitute a related party transaction or a significant asset restructuring as per regulations [13][14]

证券代码：603222 证券简称：济民健康 公告编号：2025-032 济民健康管理股份有限公司 关于参与投资创业发展基金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●投资标的名称：湖北长河智能科技创业发展合伙企业（有限合伙） ●投资金额：公司投资金额为人民币 15,000 万元 ●本次交易不构成关联交易，不构成《上市公司重大资产重组管理办法》规 定的重大资产重组。 一、对外投资概述 为培育和整合具有潜力的标的资产，助力济民健康管理股份有限公司（以下 简称"公司"或"济民健康"）产业转型升级，公司拟与上海临珺电子科技有限 公司（以下简称"上海临珺"）、长江云河（湖北）创业投资基金有限公司（以 下简称"长河湖北创投"）联合采用增资的方式对湖北长河智能科技创业发展合 伙企业（有限合伙）（以下简称"长河智能"）投资 31,000 万元，其中，公司 拟作为有限合伙人加入长河智能并认购长河智能新增合伙份额人民币 15,000 万 元，上海临珺拟作为有限合伙人加入长河智能并认购长河智能新增合伙份额人民 币 8, ...

以上内容详见公司于 2024 年 11 月 8 日在上海证券交易所网站披露的《公司 投资设立国科济民新质生产力创业投资合伙企业 (有限合伙)的公告》（公告编号： 2024-068）。 证券代码：603222 证券简称：济民健康 公告编号：2025-031 济民健康管理股份有限公司 关于终止投资产业基金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次拟对外投资概述 2024 年 11 月 7 日，济民健康管理股份有限公司（以下简称"公司"或"济 民健康"）第五届董事会第十五次会议审议通过了《关于投资设立国科济民新质 生产力创业投资合伙企业(有限合伙)的议案》，拟与上海国科龙晖私募基金管理 有限公司（以下简称"国科龙晖私募基金"）共同发起设立以处于成长期科技创 新型企业为投资标的的产业投资基金—国科济民新质生产力创业投资合伙企业 （有限合伙）（以下简称"产业基金"）。 产业基金总认缴出资额为 50,000 万元，国科龙晖私募基金为普通合伙人、 管理人和执行事务合伙人，出资 50 万元；济民健康为有限合伙人，出资 4 ...

第五届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况： 证券代码：603222 证券简称：济民健康 公告编号：2025-030 济民健康管理股份有限公司 上述议案内容详见公司指定信息披露媒体和上海证券交易所网站同日公告。 特此公告。 济民健康管理股份有限公司董事会 2025 年 6 月 17 日 济民健康管理股份有限公司（以下简称"公司"）第五届董事会第十九次会议 于 2025 年 6 月 15 日以通讯表决方式召开，会议通知于 2025 年 6 月 12 日通过电 话、邮件及书面形式发出，本次会议由董事李丽莎女士主持，应出席董事 7 名， 实际出席董事 7 名。会议的召集，召开符合《公司法》和《公司章程》的有关规 定，会议合法有效。 二、董事会会议审议情况： 经过与会董事认真审议，形成如下决议： 1、以 7 票赞成，0 票反对，0 票弃权，0 票回避，审议通过了《关于终止 投资产业基金的议案》； 2、以 7 票赞成，0 票反对，0 票弃权，0 票回避，审议通过了《关于 ...

证券代码：603222 证券简称：济民健康 公告编号：2025-029 济民健康管理股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/3/29 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 个月 12 | | 预计回购金额 | 10,000万元~20,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 200.55万股 | | 累计已回购股数占总股本比例 | 0.38% | | 累计已回购金额 | 1,208.90万元 | | 实际回购价格区间 | 5.87元/股~6.13元/股 | 2025 年 5 月，公司通过集中竞价交易方式回购股份 300,000 股，回购股份占 公司总股本的比例为 0.057%，成交的最高价为 5.88 元/股，最低价为 5.87 元/股， 支付的 ...